sad
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
State-mandated coverage for venipuncture and capillary specimen collection for lead screening for children under six as required by Rhode Island law; describes coverage, coding, and reimbursement instructions for commercial products (not applicable to Medicare Advantage).
Policy notes that prior authorization is not required.
Coverage Summary
Rhode Island law (RIGL 23-24.6-9) mandates screening for lead poisoning and related diagnostic evaluations for children under six (6) years of age; these services, including confirmatory venous testing when indicated, are a covered health benefit and reimbursable.
Venipuncture or capillary blood collection that is collected to be sent to a state-approved laboratory for lead screening is covered and separately reimbursable when reported with the -32 modifier for Commercial Products.
This state mandate applies to children under age 6 and generally does not apply to BlueCHiP for Medicare members; the mandate is for children who are not eligible for Medicare. Prior authorization is not required for venipuncture for lead screening.
Coverage Criteria
Billing Codes
Provider Actions & Billing Rules
Age and clinical indication documentation
Document that the specimen collection is for lead screening or lead-related diagnostic evaluation for a child under six years of age as required by Rhode Island statute and department regulations.
Prior Authorization not required
Prior Authorization is not required for venipuncture for lead screening. This was clarified in the policy.
Definitions & Background
The -32 modifier indicates that collection of blood by venipuncture or capillary collection (for example, finger, heel, or ear stick) is being billed separately for lead testing specimen collection; covered Commercial codes include 36415-32 (venous venipuncture) and 36416-32 (capillary collection).
Lead is particularly harmful to children younger than six years; screening is performed because even small amounts of lead can negatively affect development, cause learning disabilities, reduced IQ, behavioral problems, and other serious health effects.
Lead screening is conducted by a simple blood test that may be performed by finger prick (capillary) or venipuncture; if a stick (capillary) test shows a significant elevation, a confirmatory venous blood sample is generally obtained.
Medicare Applicability
Informational: Rhode Island-mandated benefits generally do not apply to BlueCHiP for Medicare members; the statutory mandate targets children under age 6 who are not eligible for Medicare.
Revision History
Policy notes that prior authorization is not required.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.